RAPP (Rapport Therapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics COGS-to-Revenue?

Rapport Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2025 was $0.00 Mil.

Rapport Therapeutics's COGS to Revenue for the three months ended in Mar. 2025 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Rapport Therapeutics's Gross Margin % for the three months ended in Mar. 2025 was N/A%.

Rapport Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Rapport Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics COGS-to-Revenue Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

COGS-to-Revenue

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial					-	-	-	-	-

Rapport Therapeutics COGS-to-Revenue Calculation

Rapport Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Rapport Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Rapport Therapeutics (NAS:RAPP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Rapport Therapeutics's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Rapport Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.